FUNDING
Belgian
Vrije Universiteit Brussel
-
Elucidation of the role of connexin proteins in hepatocyte apoptosis
2008-2009: 10.000€
Promoter: Mathieu Vinken
Co-promoter: Vera Rogiers
-
Connexin signaling research group (Alliance Research Group)
2011-2020: 10.000€
Promoters: Mathieu Vinken, Luc Leybaert
-
Liver-based in vitro models for toxicity testing and translational aspects (Strategic Research Program)
2014-2019: 450.000€
Promoter: Vera Rogiers
Co-promoters: Tamara Vanhaecke, Mathieu Vinken, Jan Gutermuth
-
Liver connexin and pannexin research group (Alliance Research Group)
2014-2026: 120.000€
Promoters: Mathieu Vinken, Bruno Cogliati
-
Panx1 as a novel biomarker for non-alcoholic steatohepatitis (Industrial Research Fund)
2016-2017: 50.000€
Promoter: Mathieu Vinken
Co-promoter: Serge Muyldermans
-
Exploiting peptides: protein binders, modulators and inhibitors for imaging and therapy (Strategic Research Program)
2019-2023: 1.220.000€
Promoter: Steven Ballet
Co-promoters: Vicky Caveliers, Sophie Hernot, Wim Versées, Mathieu Vinken, Serge Muyldermans, Nick Devoogdt
-
Non-animal methodologies for toxicity testing of chemical compounds (Interdisciplinary Research Program)
2019-2023: 550.000€
Promoter: Tamara Vanhaecke
Co-promoters: Mathieu Vinken, Joery De Kock, Olga De Troyer, Paul Quinn
-
B-liver: The Brussels liver research to valorisation alliance (Groups of Expertise in Applied Research Program)
2020-2024: 650.000€
Promoter: Tamara Vanhaecke
Co-promoters: Leo van Grunsven, Joery De Kock, Mathieu Vinken, Hendrik Reynaert
-
Cellular communication as target and biomarker in liver disease and toxicity: from basic research towards clinical application (Methusalem program)
2021-2027: 2.100.000€
Promoter: Mathieu Vinken​
​
Scientific Fund Willy Gepts
-
Connexin hemichannels as drug targets in acute liver failure: a combined in vitro-in vivo study
2012-2016: 25.000€
Promoter: Mathieu Vinken
Co-promoters: Tamara Vanhaecke, Vera Rogiers
-
Hemichannels as novel pharmacological targets and biomarkers of cholestasis
2017-2020: 25.000€
Promoter: Mathieu Vinken
Co-promoters: Michaël Maes, Bruno Cogliati
-
Are connexins, pannexins and their (hemi)channels novel biomarkers and pharmacological targets in the prognosis and therapy of liver cancer?
2020-2023: 22.500€
Promoter: Mathieu Vinken
Co-promoters: Kaat Leroy, Bruno Cogliati
-
Can food addities cause liver damage?
2022-2025: 37.500€
Promoter: Mathieu Vinken
Innoviris
ONTOX: ontology-driven and artificial intelligence-based repeated dose toxicity testing of chemical for next
generation risk assessment
2019: 25.000€
Promoter: Mathieu Vinken
​
VLAIO
HOBOTA: high-dimensional organoid-based organ toxicity assessment
2021-2023: 1.951.707€
Promoter: Freddy Van Goethem
Co-promoters: Mathieu Vinken, Bahar Ramezanpour
​
Research Foundation Flanders
-
Role of Cx32 and Cx43 in the control of hepatocellular homeostasis: development of a long-term primary hepatocyte culture system for pharmaco-toxicological studies
2010-2011: 16.400€
Promoter: Mathieu Vinken
Co-promoter: Vera Rogiers
-
Connexin and pannexin channels: regulation, functions and applications
2010-2019: 120.000€
Promoter: Luc Leybaert
Co-promoters: Geert Bultynck, Mathieu Vinken
-
Hepatocyte-like cells derived from adult human skin progenitor cells as a potential in vitro model for the screening of drugs for liver toxicity
2013-2016: 160.000€
Promoter: Tamara Vanhaecke
Co-promoters: Mathieu Vinken, Vera Rogiers
-
Characterization of Cx43- and Panx1-based hemichannels as tissue biomarkers and pharmacological targets in acute liver failure
2014-2017: 275.236€
Promoter: Mathieu Vinken
Co-promoters: Tamara Vanhaecke, Vera Rogiers
-
Hemichannels as novel pharmacological targets in liver fibrosis
2014-2017: 360.000€
Promoter: Mathieu Vinken
Co-promoters: Elke Decrock, Luc Leybaert, Tamara Vanhaecke, Vera Rogiers
-
Are connexin and pannexin hemichannels therapeutic drug targets and diagnostic biomarkers in cholestasis?
2018-2021: 425.700€
Promoter: Mathieu Vinken
Co-promoter: Pieter Annaert
-
Nanobody-based inhibitors of connexin and pannexin hemichannels as therapeutics for the treatment of hepatic and cardiovascular diseases
2018-2021: 457.700€
Promoter: Mathieu Vinken
Co-promoters: Serge Muyldermans, Brenda Kwak
-
Light sheet fluorescence microscope in life sciences and medical research
2018-2022: 689.653,84€
Promoter: Karen Sermon
Co-promoters: Hilde Van De Velde, Ellen Goossens, Luc Baeyens, Jo Van Ginderachter, Dimitri De Bundel, Sophie Hernot, Joery De Kock, Mathieu Vinken, Tamara Vanhaecke, Robim Marcelino Rodrigues, Leo van Grunsven
-
Are connexins, pannexins and their (hemi)channels novel biomarkers and pharmacological targets in the prognosis and therapy of liver cancer?
2019-2021: 225.000€ (+ 300.000BRL from São Paulo Research Foundation)
Promoters: Mathieu Vinken, Bruno Cogliati
-
Seahorse platform: the Agilent Seahorse Flux Analyser with integrated normalization system
2020-2023: 342.415,45€
Promoter: Ann Massie
Co-promoters: Eline Menu, Mathieu Vinken, Jo Van Ginderachter, Claudia Spits, Johan Stiens, Rose Njemini, Kenno Vanommeslaeghe
-
Modelling and prediction of liver toxicity: focus on drug-induced cholestasis
2021-2025: 62.500€
Promoter: Mathieu Vinken
Co-promoters: Lindsey Devisscher, Pieter Annaert
-
Can food additives cause liver damage? A mechanistic in vitro modelling study
2022-2025: 507.000€
Promoter: Mathieu Vinken
Co-promoter: Jochem Louisse​
-
The role of pannexin1 channels in non-alcoholic steatohepatitis: therapeutic and diagnostic relevance
2023-2026: 520.000€ (+ 50.000€ for the University of São Paulo)
Promoter: Mathieu Vinken
Co-promoter: Bruno Cogliati
European
6th and 7th Framework Program: Societal Challenges
-
CarcinoGENOMICS: development of a high throughput genomics-based test for assessing genotoxic and carcinogenic properties of chemical compounds in vitro
2006-2011: 12.619.013€
Promoter: Jos Kleinjans
Co-promoters at Vrije Universiteit Brussel: Vera Rogiers, Mathieu Vinken, Tamara Vanhaecke
-
DETECTIVE: detection of endpoints and biomarkers of repeated dose toxicity using in vitro systems
2011-2015: 8.674.850,6€
Promoter: Jürgen Hescheler
Co-promoters at Vrije Universiteit Brussel: Vera Rogiers, Mathieu Vinken, Tamara Vanhaecke
-
HeMiBio: hepatic microfluidic bioreactor
2011-2015: 9.400.000€
Promoter: Catherine Verfaillie
Co-promoters at Vrije Universiteit Brussel: Vera Rogiers, Mathieu Vinken, Tamara Vanhaecke
7th Framework Program and Horizon 2020: European Research Council
-
CONNECT: connexin and pannexin channels as drug targets and biomarkers in acute and chronic liver disease (Starting Grant)
2014-2019: 1.473.928,8€
Promoter: Mathieu Vinken
-
CONNECT-2-CLINIC: pannexin nanobodies for the clinical treatment of liver disease (Proof-of-Concept Grant)
2020-2021: 150.000€
Promoter: Mathieu Vinken
Horizon 2020: Future and Emerging Technologies
-
PANACHE: production of next generation modulators of pannexins and connexins as novel therapeutics in the treatment of inflammatory cardiovascular, hepatic and joint diseases (FETopen)
2020-2024: 3.503.628,75€
Promoter: Mathieu Vinken
Co-promoters: Steven Ballet, Brenda Kwak, Maria Mayan, Rafael Gozalbes
Horizon 2020: Marie Skłodowska-Curie Actions
-
In3: an integrated interdisciplinary approach to animal-free chemical and nanomaterial safety assessment (innovative training network)
2017-2020: 3.861.963€
Promoter: Paul Jennings
Partner organization: European Society of Toxicology In Vitro (Mathieu Vinken)
-
ChOLLATERAL: generation of an adverse outcome pathway network on cholestatic liver injury for mechanism-based in vitro testing the toxicity induced by chemicals (individual fellowship)
2019-2021: individual fellowship to Vânia Vilas-Boas
Promoter: Vânia Vilas-Boas
Supervisor: Mathieu Vinken
-
3R-IMPACT: in vitro testing of the hepatotoxic potential of parenteral nutrition (co-funding of regional, national and international programmes)
2022-2024: postdoctoral fellowship to Miloš Mihajlović
Promoter: Miloš Mihajlović
Supervisor: Mathieu Vinken
Horizon 2020: Societal Challenges
-
ONTOX: ontology-driven and artificial intelligence-based repeated dose toxicity testing of chemicals for next generation risk assessment
2021-2026: 17.211.050€
Promoter: Mathieu Vinken
Co-promoter at Vrije Universiteit Brussel: Tamara Vanhaecke
​​
Horizon Europe: Innovative Health Initiative
-
VICT3R: developing and implementing virtual control groups to reduce animal use in toxicology research
2024-2027: 27.886.213,75€
Promoter: Ferran Sanz
Co-promoter at Vrije Universiteit Brussel: Mathieu Vinken​
Cosmetics Europe
-
Development and testing of a repeated dose toxicity ontology model for chemical risk assessment purposes: liver effects as a case study
2018-2021: 906.386€ (324.000€ for Vrije Universiteit Brussel)
Promoter: Mathieu Vinken
Co-promoters: Aldert Piersma, Bob van de Water, Mark Cronin, Nynke Kramer, Dinant Kroese, George Daston, Chihae Yang
Brazilian
Universidade de São Paulo
-
Connexin and pannexin channels as drug targets and biomarkers in acute and chronic liver disease
2014-2016: 163.200BRL
Promoter: Mathieu Vinken
São Paulo Research Foundation
-
Connexins and pannexins as drug targets and biomarkers in liver disease
2014-2017: 2.373.910BRL
Promoter: Mathieu Vinken
Co-promoter: Bruno Cogliati
USA
Center for Alternatives to Animal Testing
-
Establishment and in vitro testing of an adverse outcome pathway of cholestatic liver injury
2018-2020: 40.000$
Promoter: Mathieu Vinken
-
An animal-free approach for human safety testing of food additives
2023-2024: 40.000$
Promoter: Mathieu Vinken
Alternatives Research and Development Foundation
-
An animal-free approach for human safety testing of food additives
2021-2022: 40.000$
Promoter: Mathieu Vinken
-
A human-relevant and AOP-driven in vitro approach for studying the cholestatic potential of micro- and nanoplastics
2023-2024: 40.000$
Promoter: Mathieu Vinken